On December 10, 2009, Fukuoka, Masayoshi; Yokogawa, Tatsushi; Miyahara, Seiji; Miyakoshi, Hitoshi; Yano, Wakako; Taguchi, Junko; Takao, Yayoi published a patent.Application of 1187931-17-4 The title of the patent was Preparation of novel uracil compounds having inhibitory activity on human deoxyuridine triphosphatase or salts thereof. And the patent contained the following:
There are disclosed uracil compounds or salts thereof which have an excellent inhibitory activity on human deoxyuridine triphosphatase (dUTPase) and are useful as therapeutic agents for treating diseases caused by dUTPase, e.g. as anti-tumor agents. There are specifically disclosed uracil compounds represented by general formula [I; n = 1-3 integer; X = a bond, O, S, C2-6 alkenylene, (un)substituted divalent aromatic hydrocarbon group, (un)substituted and (un)saturated divalent heterocyclic group; Y = a bond, C1-8 linear or branched alkylene optionally having cycloalkylidene structure on one of the carbon atoms; Z = SO2NR1R2, NR3SO2R4; R1, R2 = C1-6 alkyl, (un)substituted aralkyl wherein in case where the aromatic hydrocarbon group of the aralkyl is Ph, the Ph and its substituents together form a condensed bicyclic hydrocarbon group; or NR1R2 form (un)substituted saturated heterocyclic ring; R3 = H, C1-6 alkyl; R4 = each (un)substituted aromatic hydrocarbon group or unsaturated heterocyclic group] or salts thereof. Thus, 6.8 g N-(3-(cyclopropylmethoxy)benzyl)-3-(methoxymethoxy)propane-1-sulfonamide was dissolved in 20 mL CH2Cl2, treated with a solution of 6.7 mL 1.0 M BCl3/CH2Cl2 at 0°, stirred at room temperature for 1.5 h, concentrated under reduced pressure, redissolved in 25 mL CH2Cl2, treated with a solution of 7.1 g 2,4-bis(trimethylsilyloxy)pyrimidine in 150 mL CH2Cl2 and 180 mg iodine, and heated at reflux for 95° for 3.5 h to give, after workup and silica gel chromatog., 42% N-(3-(cyclopropylmethoxy)benzyl)-3-((2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methoxy)propane-1-sulfonamide (II). II and (R)-N-(1-(3-(cyclopropylmethoxy)-4-fluorophenyl)propyl)-3-((2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methoxy)propane-1-sulfonamide (III) showed IC50 of 0.33 and 0.03 μM, resp., against human deoxyuridine triphosphatase. The experimental process involved the reaction of (R)-1-(2-Bromophenyl)ethanamine hydrochloride(cas: 1187931-17-4).Application of 1187931-17-4
The Article related to antitumor uracil derivative preparation, sulfonamide containing uracil derivative preparation inhibitor human deoxyuridine triphosphatase, uracil derivative preparation inhibitor human deoxyuridine triphosphatase, dioxodihydropyrimidinylmethoxypropanesulfonamide preparation inhibitor human deoxyuridine triphosphatase and other aspects.Application of 1187931-17-4
Referemce:
Bromide – Wikipedia,
bromide – Wiktionary